RU2768283C2 - Семаглутид при сердечно-сосудистых состояниях - Google Patents

Семаглутид при сердечно-сосудистых состояниях Download PDF

Info

Publication number
RU2768283C2
RU2768283C2 RU2018140900A RU2018140900A RU2768283C2 RU 2768283 C2 RU2768283 C2 RU 2768283C2 RU 2018140900 A RU2018140900 A RU 2018140900A RU 2018140900 A RU2018140900 A RU 2018140900A RU 2768283 C2 RU2768283 C2 RU 2768283C2
Authority
RU
Russia
Prior art keywords
semaglutide
mace
subject
paragraphs
fatal
Prior art date
Application number
RU2018140900A
Other languages
English (en)
Russian (ru)
Other versions
RU2018140900A3 (enExample
RU2018140900A (ru
Inventor
Олуф Кристиан Хёйбьерг ХАНСЕН
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2768283(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2018140900A publication Critical patent/RU2018140900A/ru
Publication of RU2018140900A3 publication Critical patent/RU2018140900A3/ru
Application granted granted Critical
Publication of RU2768283C2 publication Critical patent/RU2768283C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
RU2018140900A 2016-04-28 2017-04-28 Семаглутид при сердечно-сосудистых состояниях RU2768283C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16167458.5 2016-04-28
EP16167458 2016-04-28
EP16188262.6 2016-09-12
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (3)

Publication Number Publication Date
RU2018140900A RU2018140900A (ru) 2020-05-28
RU2018140900A3 RU2018140900A3 (enExample) 2020-09-28
RU2768283C2 true RU2768283C2 (ru) 2022-03-23

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018140900A RU2768283C2 (ru) 2016-04-28 2017-04-28 Семаглутид при сердечно-сосудистых состояниях

Country Status (24)

Country Link
US (3) US20190134162A1 (enExample)
EP (1) EP3448416B1 (enExample)
JP (1) JP7221694B2 (enExample)
KR (3) KR102778218B1 (enExample)
CN (1) CN109069589B (enExample)
AU (2) AU2017256774B2 (enExample)
BR (1) BR112018072020A2 (enExample)
CA (1) CA3022535A1 (enExample)
CL (1) CL2018003045A1 (enExample)
DK (1) DK3448416T3 (enExample)
ES (1) ES2928007T3 (enExample)
HR (1) HRP20221150T1 (enExample)
HU (1) HUE060040T2 (enExample)
IL (1) IL262390B1 (enExample)
MA (1) MA44762A (enExample)
MX (1) MX2018012700A (enExample)
MY (1) MY202967A (enExample)
PH (1) PH12018502274B1 (enExample)
PL (1) PL3448416T3 (enExample)
RS (1) RS63630B1 (enExample)
RU (1) RU2768283C2 (enExample)
SI (1) SI3448416T1 (enExample)
WO (1) WO2017186896A1 (enExample)
ZA (2) ZA202507394B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
WO2020127950A1 (en) * 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2013037690A1 (en) * 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EA201201508A1 (ru) * 2010-05-05 2013-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированная терапия
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
RU2013131913A (ru) * 2010-12-16 2015-01-27 Ново Нордиск А/С Твердые композиции, содержащие агонист glp и соль n-(2-гидроксибензоил)амино)каприловой кислоты
WO2013037690A1 (en) * 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAMIAN GARDE: "Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes ", Fierce Biotech, 10.07.2015, найдено в Интернет [26.09.2020] URL: <https://www.fiercebiotech.com/biotech/novo-nordisk-successfully-completes-first-phase-3a-trial-semaglutide-people-type-2-diabetes>. *
HALIMI S: "Securite cardiovasculaire des incretines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue", MEDECINE DES MALADIES METABOLIQUES, 01.12.2015, v. 9, no. 8, p.768-775, DOI: 10.1016/S1957-2557(15)30265-0. *
HALIMI S: "Securite cardiovasculaire des incretines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue", MEDECINE DES MALADIES METABOLIQUES, 01.12.2015, v. 9, no. 8, p.768-775, DOI: 10.1016/S1957-2557(15)30265-0. SCHEEN A. J. "Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists", THE LANCET DIABETES AND ENDOCRINOLOGY, 01.09.2015, v.3, no. 9, p. 667-669, DOI: 10.1016/S2213-8587(15)00256-9. *
SCHEEN A. J. "Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists", THE LANCET DIABETES AND ENDOCRINOLOGY, 01.09.2015, v.3, no. 9, p. 667-669, DOI: 10.1016/S2213-8587(15)00256-9. *

Also Published As

Publication number Publication date
RU2018140900A3 (enExample) 2020-09-28
CA3022535A1 (en) 2017-11-02
KR102778218B1 (ko) 2025-03-10
HUE060040T2 (hu) 2023-01-28
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
JP2019514925A (ja) 2019-06-06
AU2017256774A1 (en) 2018-11-01
WO2017186896A1 (en) 2017-11-02
MY202967A (en) 2024-05-31
ZA202507395B (en) 2025-09-25
EP3448416A1 (en) 2019-03-06
CN109069589A (zh) 2018-12-21
BR112018072020A2 (pt) 2019-02-12
SI3448416T1 (sl) 2022-10-28
CL2018003045A1 (es) 2018-12-14
KR20250038818A (ko) 2025-03-19
HRP20221150T1 (hr) 2022-11-25
AU2017256774B2 (en) 2024-07-11
AU2024227113A1 (en) 2024-10-31
MA44762A (fr) 2019-03-06
PL3448416T3 (pl) 2022-11-07
DK3448416T3 (da) 2022-10-03
MX2018012700A (es) 2019-01-30
ES2928007T3 (es) 2022-11-14
RS63630B1 (sr) 2022-10-31
EP3448416B1 (en) 2022-08-10
CN109069589B (zh) 2022-09-06
IL262390A (en) 2018-12-31
US20250288649A1 (en) 2025-09-18
JP7221694B2 (ja) 2023-02-14
PH12018502274A1 (en) 2019-09-09
KR20220147712A (ko) 2022-11-03
US20250262281A1 (en) 2025-08-21
ZA202507394B (en) 2025-09-25
KR20180135012A (ko) 2018-12-19
RU2018140900A (ru) 2020-05-28
PH12018502274B1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
RU2768283C2 (ru) Семаглутид при сердечно-сосудистых состояниях
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
CN110022935A (zh) 用于心血管病况的德谷胰岛素
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
WO2017149105A1 (en) Liraglutide in renal conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
HK1261741B (en) Semaglutide in cardiovascular conditions
HK1261741A1 (en) Semaglutide in cardiovascular conditions
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions